Hatim Husain, MD

Articles

Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC

May 5th 2022

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Updates in Treatment of HER2 Mutant NSCLC

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Challenges Associated with Molecular Testing in NSCLC

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Dr. Husain on Common Misconceptions in Lung Cancer

June 5th 2020

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Dr. Husain on the Evolution of Liquid Biopsies in Lung Cancer

April 20th 2020

Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.

Dr. Husain on Ongoing Research Evaluating Plasma-Based Testing in Lung Cancer

March 25th 2020

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Dr. Husain on the Increased Use of and Challenges With Utilizing Liquid Biopsies

March 6th 2020

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Dr. Husain on Liquid Biopsy Versus Tissue Biopsy in NSCLC

February 20th 2020

Hatim Husain, MD, discusses the utility of liquid biopsy versus tissue biopsy in non–small cell lung cancer.

Dr. Husain on Plasma-Based Testing in Lung Cancer

June 20th 2018

Hatim Husain, MD, assistant professor of Medicine, Moores Cancer Center, University of California, San Diego, discusses plasma-based testing in lung cancer.

Dr. Husain on the Future of Monitoring T790M in Lung Cancer

March 24th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at the University of California San Diego Moores Cancer Center, discusses the future of monitoring the emergence of EGFR T790M circulating tumor DNA in urine from EGFR-mutated non–small cell lung cancer (NSCLC).

Dr. Husain on Monitoring the Emergence of T790M in Lung Cancer

January 6th 2017

Hatim Husain, MD, assistant professor of Hematology-Oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR-mutated NSCLC.

Time Management: Balancing Clinical Education With Scientific Research

June 15th 2012

With careful attention to detail and conscientious efforts, clinical skills are likely to be transferable from clinical education to meeting research goals.